• This record comes from PubMed

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

. 2017 Feb ; 52 (2) : 216-221. [epub] 20160919

Language English Country Great Britain, England Media print-electronic

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/pmid27643872

In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed <6 months (5.7 months) compared with those relapsing ⩾12 months after ASCT (12.6 months, P=0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P<0.0001), 10.0 (P=0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and >2: 5.3 months (P=0.0007). In multivariate analysis, tIPI >2, achievement of response and remission lasting <6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.

Comment In

PubMed

See more in PubMed

J Clin Oncol. 1999 Apr;17(4):1244 PubMed

Blood. 2004 Jan 1;103(1):275-82 PubMed

J Clin Oncol. 2010 Sep 20;28(27):4184-90 PubMed

Ann Oncol. 2008 Nov;19(11):1935-40 PubMed

Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85 PubMed

Blood. 2012 Nov 15;120(20):4256-62 PubMed

Br J Haematol. 2016 Jul;174(2):235-48 PubMed

Ann Hematol. 2014 Aug;93(8):1345-51 PubMed

J Clin Oncol. 2011 Apr 1;29(10):1342-8 PubMed

Lancet Oncol. 2014 Jun;15(7):757-66 PubMed

Bone Marrow Transplant. 2015 Oct;50(10):1286-92 PubMed

J Clin Oncol. 2012 Dec 20;30(36):4462-9 PubMed

Blood. 1992 Oct 15;80(8):2142-8 PubMed

Bone Marrow Transplant. 2016 Jan;51(1):51-7 PubMed

Mol Cancer. 2015 Dec 11;14:207 PubMed

Bone Marrow Transplant. 2016 Mar;51(3):365-71 PubMed

J Clin Oncol. 2011 Nov 1;29(31):4079-87 PubMed

Bone Marrow Transplant. 2014 May;49(5):671-8 PubMed

Am Soc Clin Oncol Educ Book. 2015;:e449-57 PubMed

Ann Hematol. 2012 Jun;91(6):931-9 PubMed

Br J Haematol. 2014 Mar;164(5):668-74 PubMed

Expert Rev Anticancer Ther. 2015 Apr;15(4):439-51 PubMed

Am J Hematol. 2013 Oct;88(10):890-4 PubMed

Find record

Citation metrics

Logged in users only

Archiving options